• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PI3K/AKT/mTOR通路的激活导致乳腺癌耐药。

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

作者信息

Dong Chao, Wu Jiao, Chen Yin, Nie Jianyun, Chen Ceshi

机构信息

Department of the Second Medical Oncology, The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital, Kunming, China.

Department of Urology, Changhai Hospital, Navy Medical University, Shanghai, China.

出版信息

Front Pharmacol. 2021 Mar 15;12:628690. doi: 10.3389/fphar.2021.628690. eCollection 2021.

DOI:10.3389/fphar.2021.628690
PMID:33790792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8005514/
Abstract

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.

摘要

尽管化疗、靶向治疗和内分泌治疗可降低大多数乳腺癌患者的疾病复发率，但许多患者会出现获得性耐药。PI3K/AKT/mTOR通路的过度激活与耐药性及癌症进展相关。目前，一些靶向PI3K/AKT/mTOR的药物正在临床试验中进行研究，将它们与标准疗法联合使用以克服乳腺癌的获得性耐药。在本综述中，我们总结了PI3K/AKT/mTOR通路在耐药性中的关键作用、PI3K/AKT/mTOR抑制剂的研发情况，以及克服乳腺癌对标准疗法获得性耐药的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/815049640279/fphar-12-628690-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/fddb94152d60/fphar-12-628690-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/139f1af4bd67/fphar-12-628690-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/c7c06ee199aa/fphar-12-628690-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/815049640279/fphar-12-628690-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/fddb94152d60/fphar-12-628690-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/139f1af4bd67/fphar-12-628690-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/c7c06ee199aa/fphar-12-628690-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5430/8005514/815049640279/fphar-12-628690-g004.jpg

相似文献

1
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.PI3K/AKT/mTOR通路的激活导致乳腺癌耐药。
Front Pharmacol. 2021 Mar 15;12:628690. doi: 10.3389/fphar.2021.628690. eCollection 2021.
2
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.针对雌激素受体阳性乳腺癌中的 PI3K/AKT/mTOR 通路。
Cancer Treat Rev. 2014 Aug;40(7):862-71. doi: 10.1016/j.ctrv.2014.03.004. Epub 2014 Mar 26.
3
A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy.PI3K/AKT/mTOR信号通路抑制剂克服乳腺癌治疗耐药性的研究进展
Curr Med Chem. 2025;32(10):1865-1873. doi: 10.2174/0109298673327425240815065221.
4
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.克服癌症治疗获得性耐药：聚焦 PI3K/AKT/mTOR 通路。
Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Epub 2013 Feb 3.
5
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?PI3K/AKT/mTOR通路抑制剂：乳腺癌治疗的理想联合伙伴？
Expert Rev Anticancer Ther. 2015 Jan;15(1):51-68. doi: 10.1586/14737140.2015.961429. Epub 2014 Oct 11.
6
PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.辅助内分泌治疗后原发和相应转移性乳腺癌中 PI3K/AKT/mTOR 通路的激活。
Int J Cancer. 2014 Sep 1;135(5):1257-63. doi: 10.1002/ijc.28769. Epub 2014 Feb 27.
7
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.针对人类癌症的靶向治疗，攻击 PI3K/Akt/mTOR 信号通路。
Semin Cancer Biol. 2022 Oct;85:69-94. doi: 10.1016/j.semcancer.2021.06.019. Epub 2021 Jun 25.
8
Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer.晚期雌激素受体阳性乳腺癌对PI3K/AKT/mTOR通路靶向抑制剂的耐药性
Cancers (Basel). 2024 Jun 18;16(12):2259. doi: 10.3390/cancers16122259.
9
Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.PI3K 和 mTOR 抑制剂作为乳腺癌抗癌药物的现状和未来展望。
Curr Cancer Drug Targets. 2013 Feb;13(2):175-87. doi: 10.2174/1568009611313020007.
10
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.乳腺癌阿那曲唑耐药的分子特征： Akt/mTOR 通路在新出现的或获得性耐药中的关键作用，以及联合应用变构 Akt 抑制剂 MK-2206 和芳香酶抑制剂的重要性。
Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

引用本文的文献

1
Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance.解读腺苷脱氨酶作用于RNA（ADARs）在癌症发病机制、肿瘤免疫逃逸和耐药性中的机制性作用。
Front Immunol. 2025 Aug 7;16:1621585. doi: 10.3389/fimmu.2025.1621585. eCollection 2025.
2
Hydroxytyrosol Reprograms the Tumor Microenvironment in 3D Melanoma Models by Suppressing ERBB Family and Kinase Pathways.羟基酪醇通过抑制ERBB家族和激酶信号通路对三维黑色素瘤模型中的肿瘤微环境进行重编程。
Int J Mol Sci. 2025 Jul 20;26(14):6957. doi: 10.3390/ijms26146957.
3
The Role of p66Shc in Cancer: Molecular Mechanisms and Therapeutic Implications.

本文引用的文献

1
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells.PI3K 抑制对头颈部癌细胞放疗反应的影响。
Sci Rep. 2020 Oct 1;10(1):16208. doi: 10.1038/s41598-020-73249-z.
2
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.Akt抑制与激素受体阳性、HER2阴性乳腺癌肿瘤微环境内有利的免疫谱变化相关。
Front Oncol. 2020 Jun 16;10:968. doi: 10.3389/fonc.2020.00968. eCollection 2020.
3
Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.
p66Shc在癌症中的作用：分子机制与治疗意义
J Cell Mol Med. 2025 Jul;29(14):e70737. doi: 10.1111/jcmm.70737.
4
Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.脂质代谢与铁死亡相关指标在激素受体阳性乳腺癌预后及免疫治疗反应预测中的多队列验证
Int J Biol Sci. 2025 Jun 9;21(9):3968-3992. doi: 10.7150/ijbs.113213. eCollection 2025.
5
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes.通过同时抑制关键代谢酶对癌细胞进行协同靶向治疗。
Cell Death Differ. 2025 Jun 23. doi: 10.1038/s41418-025-01532-5.
6
Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer: a systematic review and meta-analysis.PI3K抑制剂联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：一项系统评价和荟萃分析。
Front Oncol. 2025 Jun 4;15:1556978. doi: 10.3389/fonc.2025.1556978. eCollection 2025.
7
The MDA-MB-231 Breast Cancer Cell Secretomes Modify Metabolomes of Breast Microbiome.MDA-MB-231乳腺癌细胞分泌组改变乳腺微生物组的代谢组。
Int J Mol Sci. 2025 May 22;26(11):5003. doi: 10.3390/ijms26115003.
8
Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.基于高级分层计算建模的铂（II）纳米复合物合理开发，以改善肺癌治疗。
Adv Funct Mater. 2025 Feb 12;35(7). doi: 10.1002/adfm.202411334. Epub 2024 Sep 27.
9
Penicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway.青霉氮杂菲酮C通过MDM2/p53/SLC7A11/GPX4途径在三阴性乳腺癌细胞中引发铁死亡。
Discov Oncol. 2025 Jun 2;16(1):983. doi: 10.1007/s12672-025-02687-w.
10
Drug-tolerant persister cells in acute myeloid leukemia: pressing challenge and promising new strategies for treatment.急性髓系白血病中的药物耐受性持久细胞：紧迫的挑战与有前景的新治疗策略
Front Med (Lausanne). 2025 May 14;12:1586552. doi: 10.3389/fmed.2025.1586552. eCollection 2025.
新型 PI3K/Akt/mTOR 通路抑制剂联合放疗：针对携带突变 RAS 基因的非小细胞肺癌的策略。
Life Sci. 2020 Aug 15;255:117816. doi: 10.1016/j.lfs.2020.117816. Epub 2020 May 23.
4
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors.使用磷脂酰肌醇-3-激酶（PI3K）、蛋白激酶B（AKT）或雷帕霉素哺乳动物靶点（mTOR）抑制剂使癌症对放疗增敏
Cancers (Basel). 2020 May 18;12(5):1278. doi: 10.3390/cancers12051278.
5
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?序贯内分泌治疗转移性乳腺癌：在 CDK4/6 抑制剂治疗进展后我们该怎么做？
Curr Oncol Rep. 2020 May 16;22(6):57. doi: 10.1007/s11912-020-00917-8.
6
ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma.膜联蛋白A6通过抑制鼻咽癌中的PI3K/AKT/mTOR信号通路促进自噬，从而导致放射抗性。
Front Cell Dev Biol. 2020 Apr 16;8:232. doi: 10.3389/fcell.2020.00232. eCollection 2020.
7
Immunotherapy for Breast Cancer: First FDA Approved Regimen.乳腺癌免疫疗法：首个获美国食品药品监督管理局批准的方案。
Discoveries (Craiova). 2019 Mar 31;7(1):e91. doi: 10.15190/d.2019.4.
8
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR/HER2 Metastatic Breast Cancer.PIK3CA突变在激素受体/人表皮生长因子受体2转移性乳腺癌中的预后及预测价值的系统文献综述
Clin Breast Cancer. 2020 Jun;20(3):e232-e243. doi: 10.1016/j.clbc.2019.08.011. Epub 2019 Sep 10.
9
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.在PTEN缺失的肿瘤中单独靶向PI3Kβ以及将其与化疗或免疫疗法联合使用。
Oncotarget. 2020 Mar 17;11(11):969-981. doi: 10.18632/oncotarget.27503.
10
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining.双PI3K/mTOR抑制剂NVP-BEZ235增强头颈部鳞状细胞癌（HNSCC）细胞系的放射敏感性，原因是其通过非同源末端连接抑制双链断裂（DSB）修复。
Cancers (Basel). 2020 Feb 18;12(2):467. doi: 10.3390/cancers12020467.